Roberto Wandenkolk Vieira, the President of Oncology at Corcept Therapeutics Inc., has made notable stock transactions as reported in a recent filing. On October 2, 2026, Vieira acquired 8,333 shares of common stock at a price of $21.63 per share. Additionally, he sold 5,233 shares at prices ranging from $114.03 to $117.22. This activity is significant as it may indicate Vieira's strategic positioning within the company.
Corcept Therapeutics, based in Redwood City, California, is engaged in the pharmaceutical preparations sector. The company focuses on developing and commercializing innovative treatments for patients with serious disorders. Its stock is traded under the symbol CORT.
The recent filing, accession number 0001193125-26-414688, details Vieira's transactions. He acquired 8,333 shares through a stock option that vested and became exercisable. The filing also notes that he sold 5,233 shares under a 10b5-1 plan, which was adopted prior to his appointment as an officer of the company.
Following these transactions, Vieira now owns a total of 133,334 shares of Corcept Therapeutics. Such transactions by executives can often provide insights into their confidence in the company's future performance and strategic direction.
The filing does not specify what actions may follow these transactions, leaving investors and analysts to speculate on the implications for Corcept Therapeutics and its position in the pharmaceutical industry.